Market Overview

USPTO Withdraws Sequenom Patent No. 8,340,916

Related SQNM
Sequenom (SQNM) Soars: Stock Rises 6.4% - Tale of the Tape
Sequenom Grants Exclusive Promotion and Marketing Rights to Nicox for RetnaGene AMD Test in North America

Sequenom (NASDAQ: SQNM) announced Friday that the U.S. Patent and Trademark Office has withdrawn the issuance of U.S. Patent No. 8,340,916. Sequenom has been informed by the Patent and Trademark Office that issuance was withdrawn in connection with an anticipated patent interference proceeding between parties with pending patent applications or issued patents directed to similar subject matter. 

Sequenom had previously been notified that the patent would issue on December 25, 2012, with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at www.sequenom.com to which Sequenom

See full press release

Posted-In: Earnings News Guidance Management

 

Most Popular

Related Articles (SQNM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free